Maturing of renal cancer therapeutics

Journal of Clinical Oncology

Volumn 32, Issue 8, 2014, Pages 722-724

  Stadler, Walter M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; MAMMALIAN TARGET OF RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; RAPAMYCIN;

CANCER SURVIVAL; CANCER THERAPY; EDITORIAL; HUMAN; KIDNEY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; FEMALE; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; NOTE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRROLES; SIROLIMUS;

EID: 84899638990     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.1748     Document Type: Editorial

References (17)

1. Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002 (Pubitemid 34032623)
2. Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
3. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
4. Motzer RJ, Hutson TE, Tomczak P, et al: Phase III randomized trial of sunitinib malate versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma. J Clin Oncol 24, 2006 (suppl; abstr LBA3)
5. Rini BI, Bellmunt J, Clancy J, et al: Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 32:752-759, 2014
6. Hutson TE, Escudier B, Esteban E, et al: Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32:760-767, 2014
7. Booth B, Glassman R, Ma P: Oncology's trials. Nat Rev Drug Discov 2:609-610, 2003
8. Gan HK, You B, Pond GR, et al: Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst 104:590-598, 2012
9. Négrier S, Gravis G, Perol D, et al: Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): A randomised phase 2 trial. Lancet Oncol 12:673-680, 2011
10. McDermott DF, Manola J, Pins M, et al: The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC). J Clin Oncol 31, 2013 (suppl; abstr 345)
11. Sablin MP, Negrier S, Ravaud A, et al: Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol 182:29-34; discussion 34, 2009
12. Zhang L, Bhasin M, Schor-Bardach R, et al: Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS One 6:e19144, 2011
13. Hammers HJ, Verheul HM, Salumbides B, et al: Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: Evidence from a xenograft study. Mol Cancer Ther 9:1525-1535, 2010
14. Huang D, Ding Y, Zhou M, et al: Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70:1063-1071, 2010
15. Motzer RJ, Hutson TE, Olsen MR, et al: Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as firstline therapy for advanced renal cell carcinoma. J Clin Oncol 30:1371-1377, 2012
16. Motzer RJ, Nosov D, Eisen T, et al: Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: Results from a phase III trial. J Clin Oncol 31:3791-3799, 2013
17. Halabi S, Rini B, Escudier B, et al: Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer [epub ahead of print on October 8, 2013]